EUVIMEDEUVIMED entdecken
Crossref

Impact of Genomic Classifiers on Therapeutic Decision-Making in Prostate Cancer

Gustavo Daniel dos Santos Sousa Aguiar, Caroline Cavalcante Leite, Moisés de Sousa Veloso, Ana Paula Firchhof, Mirelly Cândida Cavoli Lira, Isabella Bueno Pereira da Rocha, Vanessa Fernandes Rodhe, Lais Walesca Alencar de Castro, Michel Patrik de Sousa Arruda, Isabelle Nunes Shimith da Silva

Brazilian Journal of Oncology · 26.06.2026 · 22 (CP)

DOI: 10.1055/s-0046-1825510 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Brazilian Journal of Oncology, erschienen am 26.06.2026. Verfasst von Gustavo Daniel dos Santos Sousa Aguiar und 9 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

All articles of this category (opens in new window) Address for correspondence Gustavo Daniel dos Santos Sousa Aguiar (gddaniel.sa@gmail.com)

Introduction

The clinical heterogeneity of localized prostate cancer poses a challenge in choosing between active surveillance and radical treatment. In this context, genomic tests have been increasingly incorporated as complementary tools to traditional clinical risk stratification, aiming to refine prognostic assessment and guide individualized therapeutic decisions.

Objective

To evaluate the clinical impact of genomic classifiers on risk reclassification and treatment intensity modification in patients with localized prostate cancer.

Methods

A systematic review was conducted following PRISMA guidelines, with searches performed in the PubMed, Embase, Scopus, and Web of Science databases up to July 2025. A total of 19 studies (n = 12,734 patients) were included, comprising 6 randomized clinical trials and 13 observational studies. Eligible studies addressed tumor risk classification protocols, survival outcomes, and the clinical impact of genomic classifiers. Quantitative analysis included extraction of odds ratios (OR), 95% confidence intervals (CI), and p-values. Methodological quality was assessed using the ROBIS tool, and risk of bias was evaluated using the Newcastle-Ottawa Scale.

Results

Nineteen studies (n = 12,734 patients) were included, consisting of 6 randomized clinical trials and 13 observational studies. Genomic testing led to risk reclassification in 32% of cases, with 20% reclassified to lower risk (eligible for active surveillance) and 12% to higher risk (requiring intensified treatment). Adherence to the modified therapeutic recommendations reached 78.5% (OR: 2.14; 95% CI: 1.72–2.66; p < 0.001). Prognostic accuracy of genomic tests ranged from a C-index of 0.71 to 0.84, surpassing that of clinical models alone (mean C-index: 0.65). Integration of genomic testing increased the accuracy of 5-year metastasis prediction by 28%. Study quality was considered moderate to high in 84% of publications, with low risk of bias.

Conclusion

Genomic classifiers demonstrated significant efficacy in clinical risk reclassification and therapeutic guidance in localized prostate cancer. Their integration into clinical practice enhances prognostic precision and supports a more personalized treatment approach, reducing the risks of overtreatment or undertreatment. These findings reinforce the value of incorporating genomic tools into clinical guidelines, with consideration for equitable access and cost- effectiveness. Publication History Article published online: 26 June 2026 © 2026. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution 4.0 International License, permitting copying and reproduction so long as the original work is given appropriate credit (https://creativecommons.org/licenses/by/4.0/) Thieme Revinter Publicações Ltda. Rua Rego Freitas, 175, loja 1, República, São Paulo, SP, CEP 01220-010, Brazil Bibliographical Record Gustavo Daniel dos Santos Sousa Aguiar, Caroline Cavalcante Leite, Moisés de Sousa Veloso, Ana Paula Firchhof, Mirelly Cândida Cavoli Lira, Isabella Bueno Pereira da Rocha, Vanessa Fernandes Rodhe, Lais Walesca Alencar de Castro, Michel Patrik de Sousa Arruda, Isabelle Nunes Shimith da Silva. Impact of Genomic Classifiers on Therapeutic Decision-Making in Prostate Cancer. Brazilian Journal of Oncology 2026; 22. DOI: 10.1055/s-0046-1825510

Zitieren

APA

Aguiar, G. D. D. S. S., Leite, C. C., Veloso, M. D. S., Firchhof, A. P., Lira, M. C. C., Rocha, I. B. P. D., Rodhe, V. F., Castro, L. W. A. D., Arruda, M. P. D. S., & Silva, I. N. S. D. (2026). Impact of Genomic Classifiers on Therapeutic Decision-Making in Prostate Cancer. Brazilian Journal of Oncology, 22(CP). https://doi.org/10.1055/s-0046-1825510

Vancouver

Aguiar GDDSS, Leite CC, Veloso MDS, Firchhof AP, Lira MCC, Rocha IBPD, et al. Impact of Genomic Classifiers on Therapeutic Decision-Making in Prostate Cancer. Brazilian Journal of Oncology. 2026;22(CP). doi:10.1055/s-0046-1825510

BibTeX
@article{Aguiar2026,
  author = {Aguiar, Gustavo Daniel dos Santos Sousa and Leite, Caroline Cavalcante and Veloso, Moisés de Sousa and Firchhof, Ana Paula and Lira, Mirelly Cândida Cavoli and Rocha, Isabella Bueno Pereira da and Rodhe, Vanessa Fernandes and Castro, Lais Walesca Alencar de and Arruda, Michel Patrik de Sousa and Silva, Isabelle Nunes Shimith da},
  title = {Impact of Genomic Classifiers on Therapeutic Decision-Making in Prostate Cancer},
  journal = {Brazilian Journal of Oncology},
  year = {2026},
  volume = {22},
  number = {CP},
  doi = {10.1055/s-0046-1825510}
}
Kostenlos starten →